Valion Bio (VBIO) FCF Margin Growth (1y) (2022 - 2025)
Analysis
Valion Bio (VBIO) FCF Margin Growth (1y) (2022 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1,388.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3,383.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -89.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -1,183.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 26,102.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 769.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 984.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -902,489.00 |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -215,514.00 |
| Sep 30, 2025 | -26,286.00 |
| Jun 30, 2025 | -118,306.00 |
| Mar 31, 2025 | -77,673.00 |
| Dec 31, 2024 | -23,919.00 |
| Sep 30, 2024 | -45,969.00 |
| Jun 30, 2024 | 62,298.00 |
| Mar 31, 2024 | 16,123.00 |
| Dec 31, 2023 | 4,695.00 |
| Sep 30, 2023 | -6,756.00 |
| Jun 30, 2023 | -122,580.00 |
| Mar 31, 2023 | -15,479.00 |
| Dec 31, 2022 | 16,564.00 |
| Sep 30, 2022 | 964.00 |
| Jun 30, 2022 | -12,315.00 |
| Mar 31, 2022 | -30,954.00 |